<DOC>
	<DOCNO>NCT00574756</DOCNO>
	<brief_summary>The purpose study evaluate effect ranolazine , FDA-approved medication treatment angina , heart function use echocardiography .</brief_summary>
	<brief_title>Effect Ranolazine Echocardiographic Indices Diastolic Dysfunction</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Heart Failure , Diastolic</mesh_term>
	<mesh_term>Ranolazine</mesh_term>
	<criteria>Moderate severe diastolic dysfunction , E/Ea &gt; 12 Preserved systolic function NYHA Class III QTc &gt; 450 msec enrollment Taking medication prolong QT interval potent inhibitor CYP3A Significant coronary artery disease Severe valvular disease Hepatic disease Severe kidney disease Women childbearing age Prior serious ventricular arrhythmia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>